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ABSTRACT A cohort of patients operated at the
National Cancer Center Hospital in Tokyo for rectal car-
cinoma, at or below the peritoneal reflection, was reviewed
retrospectively. The purpose was to study the risk factors
for local relapse and the patterns of local recurrence. Three
hundred fifty-one patients operated between 1993 and 2002
for rectal carcinoma, at or below the peritoneal reflection,
were analyzed. One hundred forty-five patients, with pre-
operatively staged T1 or T2 tumors without suspected
lymph nodes, underwent total mesorectal excision (TME).
Lateral lymph node dissection (LLND) was performed in
suspected T3 or T4 disease, or when positive lymph nodes
were seen; 73 patients received unilateral LLND and 133
patients received bilateral LLND. Of the 351 patients 6.6%
developed local recurrence after 5 years. TME only
resulted in 0.8% 5-year local recurrence. In lymph-node-
positive patients, 33% of the unilateral LLND group had
local relapse, significantly more (p = 0.04) than in the
bilateral LLND group with 14% local recurrence. Local
recurrence in the lateral, presacral, perineal, and anasto-
motic subsites was lower in the bilateral LLND group as
compared with in the unilateral LLND group. We conclude
that, in selected patients, surgery without LLND has a very
low local recurrence rate. Bilateral LLND is more effective
in reducing the chance of local recurrence than unilateral
LLND. Either surgical approach, with or without LLND,
requires reliable imaging during work-up.
For rectal cancer, surgery is the principal treatment in
order to cure. Total mesorectal excision (TME) removes
the primary tumor with its surrounding mesorectum as an
intact package, preventing residual tumor cells in the
mesorectum from developing into local recurrence.1,2 In
advanced lesions neoadjuvant (chemo)radiotherapy can
downstage tumors, but good surgical quality is still
essential in order to achieve total clearance of tumor
cells.3
The Japanese concept of surgical treatment of rectal
cancer has evolved from anatomical studies in which
three lymphatic flow routes were identified.4,5 The upper
route is along the superior rectal artery to the inferior
mesenteric artery; the lateral route reaches from the
middle rectal artery to the internal iliac and obturator
basins; and the downward route extends to the inguinal
lymph nodes. The upper and lateral routes were shown to
be the main two routes of rectal cancer spread, with the
peritoneal reflection as the limitation between the two
lymphatic areas.6 Consequently, lateral lymph node dis-
section (LLND) was developed in Japan in order to resect
the tumor with the primary locoregional lymph node
basins beyond the mesorectal plane.7 LLND has resulted
in better survival and lower recurrence rates than con-
ventional surgery.8,9
A problem is that the lateral lymph node routes are
anatomically close to the pelvic autonomic nerve plexus,
requiring challenging surgery to preserve these during
LLND.10 In order to prevent damage to autonomic nerves,
nowadays case-oriented policy is practised in Japan,
adopting LLND only in advanced disease at or below the
peritoneal reflection.
The aim of this study is to evaluate the treatment of
rectal cancer between 1993 and 2002 at the National
Cancer Center Hospital (NCCH), looking at patterns of
local recurrence and the risk factors for local recurrence.
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From 1993 to 2002, 923 patients were operated for
confirmed primary adenocarcinoma of the rectum at the
National Cancer Center Hospital (NCCH) in Tokyo. Sur-
gery was performed according to the guidelines of the
Japanese Research Society for Cancer of the Colon and
Rectum.11,12 The rectum was defined as located below the
lower border of the second sacral vertebra. The peritoneal
reflection is the most important landmark in defining the
location of the tumor, and low rectal carcinoma is defined
as a tumor of which the major part is located at or below
the reflection.13
For this analysis the following patients were excluded:
metastasis at the time of surgery (n = 134) and in situ
carcinoma (n = 22). Of the remaining 767 patients, only
patients with rectal carcinoma at or below the peritoneal
refection were selected, resulting in 360 patients.
Neoadjuvant chemotherapy was given to some patients
with suspicion of stage T4 disease (n = 3) in other hos-
pitals, before referral to the NCCH. Neoadjuvant
radiotherapy was not routinely given, so no patients
received preoperative radiotherapy. Sometimes in the case
of positive lymph nodes, adjuvant radiotherapy (n = 5) or
chemoradiotherapy (n = 1) was given. The nine patients
who received neoadjuvant chemotherapy and adjuvant
(chemo)radiation were excluded, leaving 351 patients for
analysis.
Methods
Until 2002 preoperative evaluation at the NCCH con-
sisted of computed tomography (CT) imaging and
endoscopic ultrasonography for all patients. Based on
preoperative imaging and intraoperative findings, standard
total mesorectal excision (TME) was performed in T1 or
T2 stage disease without suspected lymph nodes. Lateral
lymph node dissection (LLND) was added to TME in
stage T3 or T4 rectal cancer at or below the peritoneal
reflection, or when positive mesorectal lymph nodes were
suspected. Unilateral LLND was performed when the
tumor was located lateral in the low rectum, bilateral
LLND when the tumor was located centrally. When the
lateral lymph nodes were 1 cm or larger on preoperative
imaging or intraoperative findings, bilateral extended
lymph node dissection was performed, consisting of dis-
section of the complete internal iliac artery and the
autonomic nerve system. When there was no suspicion on
positive lateral lymph nodes, autonomic nerve preserva-
tion (ANP) was carried out.
Accurate documentation of lymph node status and
localization is obtained because all lymph nodes are har-
vested and recorded from the fresh specimen. The
definition of mesorectal lymph nodes is pararectal location
or in the direction of the mesentery. Lateral lymph nodes
are located along the iliac or obturator arteries.
Follow-up of all patients consisted of thorax, abdominal,
and pelvic CT imaging every 6 months. Median follow-up
of patients alive was 7.9 years.
All patients who developed local recurrence, defined as
any recurrence of rectal cancer in the lesser pelvis, were
identified. Local recurrence was diagnosed clinically,
radiologically or histologically.
For all locally recurrent patients the available preoper-
ative images and the images at the time of discovery of the
local recurrence were retrieved. A specialized oncologic
radiologist (R.G.H.B.-T.) reviewed the images. Examining
the images, the site of the local recurrence was determined.
The sites were classified into the following regions: lateral,
presacral, perineal, anterior or anastomotic. The same
borders for the respective sites were used as defined by
Roels et al.14 When no images were available, the location
of recurrence was classified using the radiology reports and
clinical data. In one patient insufficient information was
provided to determine the location of recurrence with
certainty.
Statistical Analysis
Statistical analysis was performed using the SPSS
package (SPSS 12.0 for Windows; SPSS Inc., Chicago, IL)
and R version 2.5.1. T-tests and chi-square tests were used
to compare individual variables. Survival and cumulative
recurrence incidences were estimated using the Kaplan–
Meier method. Differences between the groups were
assessed using the log-rank test. All p-values were two-
sided and considered statistically significant at 0.05 or less.
For local recurrence, cumulative incidences were calcu-
lated accounting for death as competing risk.15 Similarly,
cumulative incidences were calculated for subsite of local
recurrence, with death and other types of local recurrence
as competing risks, and for cancer-specific survival, with
death due to other causes as competing risk. Multivariate
analyses of local recurrence and overall survival were
performed by first testing the effect of covariates in a
univariate Cox regression. Covariates with trend-signifi-
cant effects (p-value \ 0.10) were then selected for
multivariate Cox regression. The following variables were
studied for local recurrence and overall survival: age, sex,
operative procedure, degree of lateral lymphadenectomy,
T-stage, mesorectal lymph node N-stage, lateral lymph
node positivity, maximum tumor diameter, differentiation,
and autonomic nerve preservation.
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RESULTS
Clinicopathology
Patient characteristics and treatment details are listed in
Table 1. Of the 351 studied patients, 145 had standard
TME surgery without LLND, 73 underwent unilateral
LLND, and 133 patients received bilateral LLND. LLND
was performed in significantly younger patients and more
often in combination with a non-sphincter-saving proce-
dure, compared with patients who had not undergone an
LLND. The tumors in the LLND patients had higher T- and
N-stages and were significantly larger. Comparing the
clinicopathological characteristics between the unilateral
and the bilateral LLND, no significant differences were
found, except that unilateral LLND was more often com-
bined with autonomic nerve preservation (ANP).
Mean lymph node harvest was 21 LNs in standard TME
(Table 1). After unilateral LLND the mean number of
recovered LNs was 38, and after bilateral LLND this was
45 (p = 0.004).
Table 2 shows the outcomes of lymph node involvement
for all 351 patients, stratified by T-stage. Overall lymph
node involvement was 42%, and lateral lymph node
TABLE 1 Clinicopathological characteristics
No LLND (n = 145) Unilateral LLND (n = 73) Bilateral LLND (n = 133) p* p**
Sex ratio (M:F) 96:49 (66:34) 47:26 (64:36) 86:47 (65:35) 0.95 0.97
Mean age (years) 61 57 57 0.03 0.98
Operation
Sphincter-saving 112 (77) 36 (49) 63 (47)
Not sphincter-saving 33 (23) 37 (51) 70 (53) \0.001 0.79
Adjuvant chemotherapy
No 139 (96) 67 (92) 121 (91)
Yes 6 (4) 6 (8) 12 (9) 0.24 0.85
T-stage
T1 52 (36) 3 (4) 3 (2)
T2 47 (32) 27 (37) 37 (28)
T3 46 (32) 40 (55) 83 (62)
T4 0 (0) 3 (4) 10 (8) \0.001 0.37
Meso LN positive
0 102 (70) 44 (60) 64 (48)
1–3 30 (21) 19 (26) 39 (29)
[4 13 (9) 10 (14) 30 (23) 0.003 0.28
Lat LN positive
No – 62 (85) 109 (82)
Yes – 11 (15) 24 (18) – 0.59
ANP
No 3 (2) 2 (3) 17 (13)
Yes 142 (98) 71 (97) 116 (87) \0.001 0.02
Differentiation
Well 75 (52) 27 (37) 50 (38)
Moderate 67 (46) 44 (60) 75 (56)
Poor 2 (2) 2 (3) 8 (6) 0.18 0.29
Tumor size
0–4 cm 106 (73) 31 (42) 42 (32)
[4 cm 39 (27) 42 (58) 91 (68) \0.001 0.12
Diss. LN (mean) 21 38 45 \0.001 0.004
Values in parentheses are percentages
* p value between no LLND, unilateral LLND, and bilateral LLND
** p value between unilateral LLND and bilateral LLND
Meso mesorectal; Lat lateral; LN lymph node; ANP autonomic nerve preservation
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involvement was 10%. Jump metastases (mesorectal lymph
nodes negative and lateral lymph nodes positive) occurred
in 3% (7/207) of the patients with LLND.
Local Recurrence
At time of last follow-up 23 of the total of 351 patients
had developed local recurrence (6.6% 5-year local recur-
rence rate). In the patients who had not undergone LLND,
only one patient (0.8%) had local recurrence at the site of
the anastomosis. In the unilateral LLND group, 12 of the
73 patients (5-year 15.4%) had local relapse. This was
more than in the bilateral LLND group, with 10 of 133
local recurrences (5-year 8.3%). In N? patients (Fig. 1),
the difference between the uni- and bilateral LLND (32.8%
versus 14.2%, respectively) was significant (p = 0.04).
In multivariate analysis (Table 3) including uni- and
bilateral LLND patients, lateral lymphadenectomy, meso-
rectal lymph node N-stage, and lateral lymph node positivity
were independent risk factors for local recurrence.
Compared with patients with bilateral LLND the relative risk
for local recurrence was 4.0 for unilateral LLND patients.
Table 4 reports the sites of the local recurrences for the
uni- and bilateral LLND groups. The rate of lateral recur-
rence in the unilateral LLND patients was 5.6%, and in the
bilateral LLND patients was 3.3%. It was noticed that
the three patients who developed lateral local recurrence on
the ipsilateral side after unilateral LLND had lower lymph
node harvest (mean 28 LNs) than the patients who devel-
oped no lateral recurrence after unilateral LLND (mean 38
LNs). However, the number of patients is too low to draw
any firm conclusion from this finding.
Distant Recurrence and Survival
At local recurrence diagnosis 40% of the unilateral
LLND patients and 60% of the bilateral LLND patients had
distant metastases. One year after local recurrence diag-
noses these figures were 70% and 80% in the uni- and
bilateral LLND patients, respectively.
TABLE 2 Lateral lymph node dissection and lymph node status, stratified by T-stage
Stage LLND LNI LNI LLNI
T1: 58 No LLND 52 (90%) N0 47 8/58 = 14% 1/58 = 2%
Upper pos 5
LLND 6 (10%) N0 3
Upper pos, lat neg 2
Upper neg, lat pos 0
Upper pos, lat pos 1
T2: 111 No LLND 47 (42%) N0 33 32/111 = 29% 7/111 = 6%
Upper pos 14
LLND 64 (58%) N0 46
Upper pos, lat neg 11
Upper neg, lat pos 2
Upper pos, lat pos 5
T3: 169 No LLND 46 (27%) N0 22 97/169 = 57% 19/169 = 11%
Upper pos 24
LLND 123 (73%) N0 50
Upper pos, lat neg 54
Upper neg, lat pos 5
Upper pos, lat pos 14
T4: 14 No LLND 0 (0%) N0 – 12/14 = 86% 8/14 = 57%
Upper pos –
LLND 14 (100%) N0 1
Upper pos, lat neg 4
Upper neg, lat pos 0
Upper pos, lat pos 8
Total: 351 207/351 = 59%* 149/351 = 42% 35/351 = 10%
LLND lateral lymph node dissection; LNI lymph node involvement (upper and lateral lymph nodes); LLNI lateral lymph node involvement;
Upper, upper lymph nodes; Lat lateral lymph nodes; pos positive; neg negative
* Percentage of patients submitted to LLND
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Figure 2 shows the survival curves of the TME-only,
and uni- and bilateral LLND patients. Overall 5-year sur-
vival was 89% for patients who had standard TME. Five-
year overall survival in the unilateral LLND group was
78%, which did not differ significantly from the bilateral
LLND group (77%) (p = 0.37).
The multivariate Cox regression analysis, when includ-
ing the uni- and bilateral LLND groups, identified T-stage,
mesorectal lymph node N-stage and lateral lymph node
positivity as independent factors for death risk.
Two years after local recurrence diagnosis 37% of the
unilateral LLND patients was still alive, as compared with
60% of the bilateral LLND patients. The number of
patients is however too low to conclude significant better














FIG. 1 Local recurrence in N? patients
TABLE 3 Multivariate analysis for local recurrence





T1 ? T2 1.00
T3 ? T4 2.99 0.84–10.73
N-stage mesorectal LN 0.008
0 pos 1.00
1–3 pos 2.71 0.75–9.85
[ 4 pos 7.22 2.01–25.94
Lateral LN status 0.007
Negative 1.00
Positive 3.53 1.41–8.85
TABLE 4 Sites of local recurrence
All patients Only N? patients









Lateral 5 (5.6) 4 (3.3) 4 (13.2) 3 (4.6)
Ipsilateral 3 (3.4) 3 (9.9)
Contralateral 2 (2.2) 1 (3.3)
Presacral 2 (2.8) 0 (0) 2 (6.7) 0 (0)
Perineal 2 (2.8) 2 (1.7) 1 (3.1) 2 (3.4)
Anterior 0 (0) 1 (0.9) 0 (0) 1 (1.8)
Anastomotic 3 (4.2) 2 (1.6) 3 (9.8) 2 (3.0)
Unknown 0 (0) 1 (0.8) 0 (0) 1 (1.4)
Total 12 10 10 9
5-Year LR rate 15.4% 8.3% 0.06 32.8% 14.2% 0.04















FIG. 2 Overall survival in all patients
Patterns of Local Recurrence in Rectal Cancer 293
DISCUSSION
Lateral lymph node dissection (LLND) was introduced
in Japan in the 1970s and results in good survival and low
local recurrence rates.7–9 Since approximately 1984 sev-
eral forms of nerve-sparing techniques, combined with
LLND, have been developed. Bilateral and even unilateral
complete autonomic nerve preservation (ANP) combined
with LLND often maintains urinary function, but reports
vary about the results in sexual function.16–20 In the many
decades of LLND surgery in Japan constant evaluation
has taken place with the purpose of preventing over-
treatment and minimizing morbidity.21 Nowadays the
policy in many Japanese hospitals is highly case-oriented,
adapting the degree of surgical resection and ANP to the
extent of cancer spread.22 Whereas in the 1970s and
1980s in the National Cancer Center Hospital (NCCH) in
Tokyo the standard procedure was to perform bilateral
LLND in case of advanced rectal cancer, lately also
unilateral LLND has been performed. The purpose of this
study was to evaluate the treatment between 1993 and
2002 at the National Cancer Center Hospital for rectal
carcinoma, at or below the peritoneal reflection, looking
at the patterns of local recurrence and the risk factors for
local recurrence. To our knowledge, there are no pub-
lished results of unilateral lymph node dissection in rectal
carcinoma.
The results of this study show 5-year local recurrence
rate of 6.6% in rectal cancer at or below the peritoneal
reflection by Japanese surgery. This primarily surgical
approach compares favorably with results in Western
countries, where neoadjuvant treatment is adopted as the
standard in order to reduce local recurrence rates. There-
fore, the Japanese concept of removing the lateral basins of
lymph nodes spread can be considered successful. How-
ever, some questions still remain to be answered. The
etiology of locally recurrent disease is not completely
understood yet.
This study, although retrospective, provides further
evidence of disease outside the TME envelope in higher-
stage tumors. Bilateral LLND (5-year local recurrence rate
14%) resulted in better local control than unilateral LLND
(5-year LR rate 33%) in N? patients. Persistent disease in
lateral lymph nodes that is left behind may account for
some of the local recurrences, as would occur in standard
TME surgery. However in that case, it would be expected
that most of the recurrences would occur originating in this
lateral basin. In this study we noted that only a part of the
local recurrences was present in the lateral side walls. Most
of the recurrences could not be explained by the anatomical
position of the lateral lymph nodes. One can only speculate
about other mechanisms of how tumor cells seed into the
surgical resection volume. Maybe removal of the lateral
lymph nodes also removes (microscopic) tumor cells which
are in transit in the lateral lymph flow route, which could
otherwise leak back into the surgical wound. This would
explain why unilateral dissection is inferior to bilateral
dissection, having more local recurrence in also the pre-
sacral, perineal, and anastomotic subsite, not only the
lateral.
The rationale behind the unilateral LLND is that the
contralateral autonomic nervous system stays untouched,
decreasing the chance of autonomic nerve injury. Studies
report that, after LLND with nerve-sparing surgery, urinary
function is maintained. Between 50% and 100% of males
are sexually active, however with compromised ejacula-
tion.16,18,19,23 This is ascribed to traction and injury to
nerves during the mobilization and electrocautery required
for LLND.18 Unfortunately we have no data on urinary and
sexual function of this cohort, being unable to report on the
results after unilateral LLND with nerve preservation.
Therefore, the question of whether functional results are
truly better remains unanswered.
The tumors of the patients who had TME without LLND
were smaller and less advanced compared with those of
LLND patients. This better staging is reflected in better
survival. That only one patient who had standard TME
surgery had local relapse (5-year local recurrence 0.8%) is
striking. The selection for low-risk disease by pre- and
intraoperative evaluation has obviously been accurate.
Interesting however, is that pathology (Tables 1 and 2)
showed that about 30% of the patients operated by TME
had T3-stage or N-positive disease. Pathology seems to
filter out more metastatic lymph nodes than preoperative
imaging, but these (micro)metastases obviously have no
oncologic consequences. Jump metastases (mesorectal
negative, lateral positive) occurred in only 3% of the
LLND patients, thus when mesorectal lymph nodes are
unsuspected, risk for lateral lymph node recurrence is very
low.
Preoperative evaluation in advanced disease is difficult.
In this study local recurrence developed on the contralat-
eral side after unilateral lymph node dissection, while these
contralateral lymph node metastases were not suspicious
on preoperative CT imaging. Meta-analysis report that
assessment of lymph node status by CT is unreliable for
clinical decision making, because the radiologist can only
look at lymph node size.24,25 Since 2002 in the NCCH
magnetic resonance imaging (MRI) has been used, which is
reported to be superior to CT because it can rely on addi-
tional morphological criteria, such as signal intensity and
border contour.26–28 Furthermore, lymph-node-specific
contrast agents or molecular imaging might play a role in
detecting micrometastases in the near future.29
In the West, (chemo)radiation is used instead of LLND.
There are no (randomized) studies comparing preoperative
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(chemo)radiotherapy and TME with LLND in similar
patients, making it difficult to make a statement about
which regimen is preferred in advanced rectal carcinoma.
Western surgeons are hesitant to do lateral lymph node
dissections for three reasons. First, in Western patients with
a higher body mass index, nerve-sparing techniques are
more difficult and the fear of excess morbidity is realistic.
Further, it is well known that lateral lymph node status is
reflective of overall mesenteric lymph node status and
lateral lymph node positivity results in poor prognosis.13,30
Lastly, although LLND has improved oncologic results in
Japanese patients in historical studies and also the current
study suggests that LLND is able to prevent residual tumor
cells from developing into local recurrence, the clinical
effectiveness of LLND has not been proved in a random-
ized fashion. Currently, the National Cancer Center
Hospital is coordinating a multicenter randomized clinical
trial comparing conventional TME with bilateral LLND in
patients with rectal carcinoma. The results are awaited with
anticipation, but it is questionable whether they will be
applicable to Western patients.
Concluding, in this study patterns of local recurrence
were evaluated in the treatment of rectal cancer, at or
below the peritoneal reflection, with selective LLND.
Overall local recurrence was 6.6% at 5 years. Local
recurrence rate after standard TME was 0.8% in low-stage
disease. In lymph-node-positive patients, 33% of the uni-
lateral LLND patients had local relapse, significantly more
than in the bilateral LLND group with 14% local recur-
rence. Either surgical approach, with or without LLND,
requires reliable imaging during work-up.
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